866-997-4948(US-Canada Toll Free)

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 201 Pages

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Keratoconjunctivitis sicca (Dry Eye)-Overview 9
Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Keratoconjunctivitis sicca (Dry Eye)-Companies Involved in Therapeutics Development 31
Alcon Laboratories Inc 31
Aldeyra Therapeutics Inc 31
Allergan Plc 31
Ascendia Pharmaceuticals LLC 32
BioLineRx Ltd 32
Cambium Medical Technologies LLC 33
Chong Kun Dang Pharmaceutical Corp 33
Clementia Pharmaceuticals Inc 34
Dompe Farmaceutici SpA 34
Elasmogen Ltd 34
HanAll Biopharma Co Ltd 35
Herantis Pharma Plc 35
Huons Global Co Ltd 36
InSite Vision Inc 36
Kala Pharmaceuticals Inc 37
KPI Therapeutics Inc 37
Kukje Pharmaceutical Industry Co Ltd 37
Laboratoires Thea SA 38
Lipicard Technologies Ltd 38
Merck & Co Inc 38
Mitotech SA 39
Nanomerics Ltd 39
Nemus Bioscience Inc 40
Novaliq GmbH 40
Ocular Therapeutix Inc 40
Oculis ehf 41
OncoNOx ApS 41
Otsuka Holdings Co Ltd 42
Quorum Innovations LLC 42
Redwood Pharma AB 43
RegeneRx Biopharmaceuticals Inc 43
Samjin Pharm Co Ltd 44
Santen Pharmaceutical Co Ltd 44
Seikagaku Corp 45
Shire Plc 45
Sun Pharma Advanced Research Company Ltd 46
Sylentis SAU 46
TearSolutions LLC 46
TopiVert Ltd 47
Vanda Pharmaceuticals Inc 47
Xigen SA 48
Keratoconjunctivitis sicca (Dry Eye)-Drug Profiles 49
ADP-355-Drug Profile 49
ADP-399-Drug Profile 50
ADX-102-Drug Profile 51
ADX-103-Drug Profile 57
AGN-223575-Drug Profile 58
AGN-232411-Drug Profile 59
AL-41A1-Drug Profile 60
AVA-3486-Drug Profile 61
AVX-012-Drug Profile 62
AX-1606-Drug Profile 63
BL-1230-Drug Profile 64
BRM-421-Drug Profile 65
cenegermin-Drug Profile 66
cinhyaluronate sodium-Drug Profile 69
Cis-Urocanic Acid-Drug Profile 70
cyclosporine-Drug Profile 72
cyclosporine-Drug Profile 75
cyclosporine-Drug Profile 77
cyclosporine-Drug Profile 78
cyclosporine-Drug Profile 79
cyclosporine-Drug Profile 80
cyclosporine-Drug Profile 81
cyclosporine SR-Drug Profile 82
dexamethasone acetate SR-Drug Profile 83
diclofenac sodium-Drug Profile 91
diquafosol tetrasodium-Drug Profile 92
Drug for Dry Eye-Drug Profile 94
ECF-843-Drug Profile 95
Elate Ocular-Drug Profile 97
ELN-22-Drug Profile 98
HL-036-Drug Profile 99
HU-007-Drug Profile 100
hyaluronate sodium-Drug Profile 101
ISV-101-Drug Profile 102
K-089-Drug Profile 103
KeraKlear-Drug Profile 104
KJ-14003-Drug Profile 105
KJ-16001-Drug Profile 106
KPI-190-Drug Profile 107
Lacripep-Drug Profile 108
Leukothera-Drug Profile 109
lifitegrast-Drug Profile 111
LME-636-Drug Profile 116
loteprednol etabonate-Drug Profile 117
LT-4003-Drug Profile 120
NB-2222-Drug Profile 121
Nov-03-Drug Profile 122
Nov-07-Drug Profile 123
OC-301-Drug Profile 124
OCX-071-Drug Profile 125
OTX-101-Drug Profile 126
OX-1001-Drug Profile 128
palovarotene-Drug Profile 129
plastoquinone decyl triphenylphosphonium bromide-Drug Profile 136
PPL-003-Drug Profile 138
Protearin-Drug Profile 140
Qi-401-Drug Profile 141
rebamipide-Drug Profile 142
RGN-259-Drug Profile 144
RP-101-Drug Profile 151
SA-001-Drug Profile 153
SHP-659-Drug Profile 154
SJP-002-Drug Profile 156
solithromycin-Drug Profile 157
ST-266-Drug Profile 171
Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders-Drug Profile 173
SYL-1001-Drug Profile 175
tadekinig alfa-Drug Profile 177
TOP-1630-Drug Profile 179
XG-104-Drug Profile 181
zucapsaicin-Drug Profile 182
Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects 184
Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products 188
Keratoconjunctivitis sicca (Dry Eye)-Product Development Milestones 189
Featured News & Press Releases 189
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Alcon Laboratories Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Aldeyra Therapeutics Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Allergan Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by BioLineRx Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Cambium Medical Technologies LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Clementia Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Dompe Farmaceutici SpA, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Elasmogen Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by HanAll Biopharma Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Herantis Pharma Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Huons Global Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by InSite Vision Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kala Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by KPI Therapeutics Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Laboratoires Thea SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Lipicard Technologies Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Merck & Co Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mitotech SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Nanomerics Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Nemus Bioscience Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Novaliq GmbH, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ocular Therapeutix Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Oculis ehf, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by OncoNOx ApS, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Otsuka Holdings Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Quorum Innovations LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Redwood Pharma AB, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Samjin Pharm Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Seikagaku Corp, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Shire Plc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Sylentis SAU, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by TearSolutions LLC, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by TopiVert Ltd, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Vanda Pharmaceuticals Inc, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Xigen SA, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H2 2017 (Contd..1), H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H2 2017 (Contd..2), H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H2 2017 (Contd..3), H2 2017
Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *